Telesis Bio is a medical devices business based in the US. Telesis Bio shares (TBIO) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.49 – a decrease of 45.56% over the previous week. Telesis Bio employs 39 staff and has a trailing 12-month revenue of around $17 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.49 |
|---|---|
| 52-week range | $0.25 - $7.29 |
| 50-day moving average | $0.47 |
| 200-day moving average | $1.58 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-30.42 |
Historical closes compared with the close of $0.49 from 2025-05-02
| 1 week (2025-04-25) | -45.56% |
|---|---|
| 1 month (2025-04-04) | 13.95% |
| 3 months (2025-02-04) | 28.95% |
| 6 months (2024-11-04) | -61.72% |
| 1 year (2024-05-03) | 48.48% |
|---|---|
| 2 years (2023-05-03) | -99.03% |
| 3 years (2022-05-03) | 74.7 |
| 5 years (2020-04-30) | N/A |
| Revenue TTM | $17 million |
|---|---|
| Gross profit TTM | $8 million |
| Return on assets TTM | -30.1% |
| Return on equity TTM | -178.99% |
| Profit margin | -267.41% |
| Book value | $-15.35 |
| Market Capitalization | $820,438 |
TTM: trailing 12 months
We're not expecting Telesis Bio to pay a dividend over the next 12 months.
Telesis Bio's shares were split on a 1:18 basis on 8 May 2024 . So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Telesis Bio shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for Telesis Bio shares which in turn could have impacted Telesis Bio's share price.
Over the last 12 months, Telesis Bio's shares have ranged in value from as little as $0.25 up to $7.2882. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Telesis Bio's is 1.567. This would suggest that Telesis Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Telesis Bio, Inc. , a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.